Remiges Ventures

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

Immunis is a private biotechnology company focused on creating innovative therapies to address immune decline associated with aging and various diseases. The company is developing a stem cell-derived treatment that utilizes human stem cells to generate specific populations of cells. These engineered cells are designed to secrete therapeutic factors that can help restore and modulate the immune system. By harnessing the potential of stem cells, Immunis aims to provide effective solutions for improving immune health and enhancing patient outcomes.

Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy, utilizing advanced technology to create therapeutic agents that address intractable eye conditions. Restore Vision's approach involves the use of chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins, allowing for increased sensitivity in patients. This technology aims to improve treatment outcomes for individuals suffering from various eye disorders, providing new hope for visual restoration.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy, utilizing advanced technology to create therapeutic agents that address intractable eye conditions. Restore Vision's approach involves the use of chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins, allowing for increased sensitivity in patients. This technology aims to improve treatment outcomes for individuals suffering from various eye disorders, providing new hope for visual restoration.

Kupando is a biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to provide cancer patients with safe and affordable immunotherapy while also creating immunostimulatory drugs to prevent infectious diseases. By targeting toll-like receptors that detect cancer and infection markers, Kupando’s therapies activate the innate immune system, allowing healthcare providers to effectively treat both cancer and infectious diseases.

Immunis is a private biotechnology company focused on creating innovative therapies to address immune decline associated with aging and various diseases. The company is developing a stem cell-derived treatment that utilizes human stem cells to generate specific populations of cells. These engineered cells are designed to secrete therapeutic factors that can help restore and modulate the immune system. By harnessing the potential of stem cells, Immunis aims to provide effective solutions for improving immune health and enhancing patient outcomes.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy, utilizing advanced technology to create therapeutic agents that address intractable eye conditions. Restore Vision's approach involves the use of chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins, allowing for increased sensitivity in patients. This technology aims to improve treatment outcomes for individuals suffering from various eye disorders, providing new hope for visual restoration.

Viage Therapeutics is a neuroscience company established in 2018, focused on developing innovative neurotherapeutics. The company aims to address psychiatric and inflammatory diseases by discovering and creating a new class of drugs targeting conditions such as depression, anxiety, and gastrointestinal disorders. Through its groundbreaking research, Viage Therapeutics seeks to provide researchers and healthcare professionals with access to novel treatments for significant unmet medical needs in these areas.

Capacity Bio is a therapeutics company dedicated to advancing the field of mitophagy, which involves the regulation of mitochondrial quality control. The company is developing a comprehensive platform aimed at creating innovative mitophagy therapeutics. By focusing on fundamental biological processes, Capacity Bio seeks to provide radical therapeutic benefits that can restore mitochondrial function in various diseases, thereby addressing critical healthcare challenges.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

Tranquis Therapeutics, Inc. is a biotechnology company focused on developing immuno-therapeutics for neurodegenerative and aging-related diseases. Established in 2016 and based in San Mateo, California, the company is rooted in neuro-immunology research from Stanford University. Its lead candidate, TQS-168, targets myeloid immune cell dysfunction associated with various nervous system disorders. The therapeutic aims to address conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. Tranquis Therapeutics is dedicated to advancing innovative treatments that could significantly alleviate the burden of these illnesses on patients and society. The company plans to initiate development for orphan diseases like ALS and FTD before expanding to more prevalent conditions such as Parkinson's and Alzheimer's disease.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

ENB Therapeutics is a biopharmaceutical company focused on developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015 and headquartered in New York, the company’s lead product, ENB-001, is a selective endothelin B receptor (ETBR) inhibitor. This innovative therapy has shown promise in preclinical studies to reduce tumor growth and enhance survival rates in cancer models by restoring T-cell infiltration into tumors and inhibiting metastasis. ENB-001 has received Orphan Drug Designation from the FDA, ensuring market exclusivity and strong intellectual property protection. The company is also developing a companion diagnostic to identify patients with over-expressed ETBR pathways, which may allow for expansion into multiple tumor types. By addressing drug resistance commonly seen in cancer patients, ENB Therapeutics aims to establish new standards of care that enhance the effectiveness of existing immunotherapy treatments and improve patient outcomes.

KisoJi Biotechnology is an early-stage biotechnology company focused on developing innovative antibodies for cancer treatment. The company utilizes a unique platform that enables the identification and visualization of a comprehensive range of antibody diversity, facilitating the selection of lead candidates with optimal characteristics. KisoJi's approach includes the use of multi-species single-domain antibody transgenic mice and AI-driven antibody fingerprinting to match specific epitopes on targets effectively. This technology supports the development of multi-specific antibodies that are robust and easily manufacturable, with the potential to enhance therapeutic outcomes for cancer and other diseases.

OMEICOS Therapeutics GmbH is a Berlin-based company founded in 2013 that specializes in developing novel therapeutics for cardiovascular diseases and other health conditions. The company focuses on small molecule therapies derived from natural metabolites of omega-3 fatty acids, which exhibit a unique mode of action. These substances activate an endogenous cardio-protective signaling pathway, providing both anti-arrhythmic effects and curative benefits by stabilizing heart rhythm and preventing electrical and structural remodeling of the heart. In addition to cardiovascular applications, OMEICOS also explores treatments for inflammatory and ophthalmic diseases, aiming to deliver safe and effective therapeutic options for various medical indications.

Mitoconix Bio Ltd, founded in 2016 and based in Jerusalem, Israel, is focused on developing innovative therapies aimed at enhancing mitochondrial health to address neurodegenerative diseases. The company seeks to improve mitochondrial functions, which are crucial for energy production, cellular metabolism, and maintaining cellular balance. Mitochondria play a vital role in neuronal health through processes such as fission and fusion, which are essential for their motility and functionality. Disruptions in these processes can lead to decreased energy production, increased oxidative stress, and cell death. Mitoconix's lead drug is a pioneering inhibitor that targets pathological mitochondrial fragmentation and dysfunction, demonstrating efficacy in animal models of Huntington’s and Parkinson’s diseases, as well as beneficial effects in patient-derived cells associated with these and Alzheimer’s disease.